We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Therapeutic goods regulation
The regulatory framework reflects and upholds the Australian community’s expectations around the safety and quality of therapeutic goods on the market.
Latest alerts
-
MAXMAN tablets pose a serious risk to your health and should not be taken.
-
Gold Max Blue capsules pose a serious risk to your health and should not be taken.
-
Dynamint X tablets pose a serious risk to your health and should not be taken.
Latest articles
-
Recall reforms update and new procedure
Recall reforms program update and preview of the PRAC Version 1.0. -
Our Guidance pages have changed
We have introduced new features to improve your experience using Guidance on our website. -
TGA's decision to not register lecanemab (LEQEMBI)
TGA has made the decision not to register lecanemab (LEQEMBI) for the treatment of patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease and Mild Alzheimer's dementia (early Alzheimer's disease).
Latest publications
-
Read our 2024 stakeholder survey report, which aims to improve the way we work with our stakeholders.
-
Communique from the meeting of the TGACC
-
This Cost Recovery Implementation Statement (CRIS) 2024-2025 provides information on how we implement, and cost recover our regulatory activities.